OTC · ENSCW
Healthcare · Biotechnology
$0.00
Down-$0.00 (-51.54%)
Updated Aug 24, 2026, 8:57 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ENSCW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ENSCW.
ENSCW research
Company profile and research snapshot.
ENSYSCE BIOSCIENCE WTS
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Mar 31, 2026
By Brad Sorensen, CFA NASDAQ: ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ: ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that have plagued the American public. Company management delivered an update that continued to center on its core strategy of
Yahoo · Mar 30, 2026
~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENSCW.
No results
No recent SID articles mention ENSCW.
